Author

B. D. Kynnap

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:whole-exome sequencing· 2 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. L. Hong· 2 shared C. M. Clinton· 2 shared D. E. Root· 2 shared E. A. Mullen· 2 shared J. S. Boehm· 2 shared K. L. Ligon· 2 shared P. C. Gokhale· 2 shared P. Keskula· 2 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. L. Hong

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivFeb 23, 2022

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper…·A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

DOI 10.1038/s42003-024-06140-6

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivDec 5, 2018

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala…·W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

DOI 10.7554/elife.44161

humanwhole-exome sequencing

𝕏 PostBluesky